

---

ALPHA UNIT

## Minutes of the 1<sup>th</sup> meeting of the Standing EFSA Working Group on lumpy skin disease

[EFSA-Q-2018-00289](#)

17 May 2018, Parma

(adopted on 22 May)

### Invited participants:

WG experts: Arjan STEGEMAN, Simon GUBBINS, Eyal KLEMENT, Paolo Calistri, Kris DECLERCQ, Annebel DEVLEESCHAUWER

EFSA: Alessandro BROGLIA, Josè CORTIÑAS, Dragop MAROJEVIC, Sotiria ANTONIOU

### 1. Welcome and apologies for absence

The participants were welcome. Apologies from Paolo Calistri.

### 2. Adoption of agenda

The agenda was adopted as agreed.

### 3. Declarations of Interest of Working Groups members

In accordance with EFSA's Policy on Independence and Scientific Decision-Making Processes and the Decision of the Executive Director on Declarations of Interest<sup>1</sup>, EFSA screened the Annual Declaration of Interest and the Specific Declaration of Interest filled in by the working group members invited for the present meeting. No Conflicts of Interest related to the issues discussed in this meeting have been identified during the screening process or at the Oral Declaration of Interest at the beginning of this meeting.

### 4. Discussion points

#### TOR 1, Vaccination duration to achieve freedom:

- Preliminary model results was presented. Simulation of epidemics after point introduction settings are indicated in the ppt, with and without vaccination.
- R0 for within herd transmission is set at 3 (broad range of values in the literature, from 1.1 from Ethiopia to 15 in Israel, but can be omitted and considering all animals in one herd infected simultaneously)

---

<sup>1</sup> <http://www.efsa.europa.eu/en/keydocs/docs/independencerules2014.pdf>

- Different replacement rates were tested
- Immunity is set for one year and then turned off, but could be also considered as life long. Difficult to simulate increasing levels of immunity, we would need data on population structure, etc.
- In the simulations shown with vaccine effectiveness at 65% and different coverage and different period of time (slide 9), after stopping vaccination the spread has a sudden peak, even higher than the initial one, and then it sets at a stable level even in the longer term (25 years) like it became endemic: apparently the infection does not go to zero even after 5 years vaccination and the few infected farms left represent a “new incursion”, thus making the spread starting again. It was decided to check the code, try to set the coverage at 100% to explore if the model manages to bring the epidemic to zero. The vaccine effectiveness could be used as 80%, which is the overall value that Eyal estimated in the region. Only after this check we can test different scenario, but first we have to be sure that we are using the right tool.
- It was discussed that the freedom from disease should be actually considered as when the model go to “real zero”. In that case the P of recurrence (the epidemic increasing again) could be either comes from a new incursion, for example if infected animals are imported from other areas or country, or if the virus survives in the environment and an animal gets infected from that.

## **TOR 2, Surveillance strategy**

- The different surveillance plans in the different 4 scenarios given are characterised by: 1) objective of surveillance, 2) test used and related Se, 3) sampling frequency, 4) design prevalence 5) targeted surveillance (risk areas or population), 6) sample size. These characteristics could be discussed in each scenario.
- The possible test to be used for surveillance purposes were discussed, clinical detection, PCR in blood or skin, and ELISA. EURL provides an overview by the available estimates of performance of different diagnostic tests (Se/Sp) compared to clinical detection. Sensitivity of the 3 tests is also influenced by the time after infection. A detailed table will be compiled.
- The role of subclinical cases was discussed. The Se of clinical detection would be lower in vaccinated areas than in unvaccinated areas, because lower chance of animals to show signs
- Sampling frequency can be derived by the epidemic curve from the model. This will vary between vaccinated or unvaccinated population. For early detection this should be adjusted in case an intervention following early detection is foreseen: the time needed for vaccine to be protected set at 21 days after vaccination, so the frequency should be reduced.
- Design prevalence: For demonstrate absence of disease: 5% as suggested by EC, see bluetongue scheme
- Risk based surveillance: at the moment we can use 2 risk factors: indoor/outdoor farms and distance from infected areas. For the indoor/outdoor farms we have the relative risk (6.5) and information about those characteristic is available for cattle population Greece. For the distance from infected areas: the kernel can be used to estimate the P the disease would escape for a given radius from infected areas. The OIE code indicate that “The surveillance should be carried out over a distance of at least 20 kilometres from the border with that infected country or zone”. We could check P for having cases out of 20km, and giving another scenario for 30km, for comparison.

- Sample size can be calculated according to design prevalence, or reversely, we may give different sample sizes and the resulting design prevalence can be estimated, what would be more informative for the RM.
- Tasks were distributed as indicated in the draft doc.

---

ALPHA UNIT

## Minutes of the 2<sup>nd</sup> meeting of the Standing EFSA Working Group on lumpy skin disease

[EFSA-Q-2018-00289](#)

19-20 June 2018, Parma

(adopted on 2<sup>nd</sup> July)

### Invited participants:

WG experts: Simon GUBBINS, Eyal KLEMENT, Paolo Calistri, Kris DECLERCQ

EFSA: Alessandro BROGLIA, Josè CORTIÑAS, Drago MAROJEVIC, Sotiria ANTONIOU

### 1. Welcome and apologies for absence

The participants were welcome. Paolo Calistri attended via web on 19<sup>th</sup> June.

### 2. Adoption of agenda

The agenda was adopted as agreed.

### 3. Declarations of Interest of Working Groups members

In accordance with EFSA's Policy on Independence and Scientific Decision-Making Processes and the Decision of the Executive Director on Declarations of Interest<sup>1</sup>, EFSA screened the Annual Declaration of Interest and the Specific Declaration of Interest filled in by the working group members invited for the present meeting. No Conflicts of Interest related to the issues discussed in this meeting have been identified during the screening process or at the Oral Declaration of Interest at the beginning of this meeting.

### 4. Discussion points

#### TOR 1a: Vaccination duration to achieve freedom

- Update results of the model based on scenario in 4 districts in Albania were presented, and they were sensible also from the epidemiological, and biological point of view
- Agreed to run scenarios for Greece and Bulgaria, testing differences in temperature data in the period 2013-2017, vaccination effectiveness 80% , coverage 70% and 90%, duration of vaccination 2, 3, 5 years, for a whole timeline of 10 years.

---

<sup>1</sup> <http://www.efsa.europa.eu/en/keydocs/docs/independencerules2014.pdf>

## **TOR 1b: Probability of recurrence of LSD**

Two scenarios discussed:

- If the disease is not brought to null with vaccination: agreed to estimate the P of recurrence derived by the model.
- If the disease is brought to null with vaccination: rank of possible reintroduction pathways, 1) introduction of infected animals, then P of introduction based on P on country of origin and amount of animals moved; 2) role of wildlife 3) role of vectors both for introduction and for maintenance in the environment; 4) windborne transmission. Description of this part to be expanded with literature references.

## **TOR 2: Surveillance strategy**

- For the definition of the threshold for early detection the case of Serbia as quickest reaction to disease was considered. The prevalence in the surveillance zone when the first outbreak was detected could be used as threshold for detection for early detection.
- Data compiled by EURL on SE and SP of different tests for LSD were revised. Se for clinical detection was discussed and value of Se 75% agreed. ELISA performance was discussed, and related value of DSe for commercial ELISA (83% ).
- Risk based surveillance to be set according to the P of the disease escaping different radius from infected area.
- The four scenarios given by EC were discussed and the elements of surveillance assessed. The sample size and frequency has to be estimated for each of those.

Tasks were distributed as indicated in the draft doc circulated after the meeting.

Next WG meeting is planned via web on 14<sup>th</sup> August

---

ALPHA UNIT

## Minutes of the 3<sup>rd</sup> tele-meeting of the Standing EFSA Working Group on lumpy skin disease

[EFSA-Q-2018-00289](#)

14<sup>th</sup> August 2018, Parma

(adopted on 16/08/2018)

### Invited participants:

WG experts: Arjan STEGEMAN, Simon GUBBINS, Paolo Calistri, Kris DECLERCQ, Annebel DEVLEESCHAUWER

EFSA: Alessandro BROGLIA

### 1. Welcome and apologies for absence

The participants were welcome.

### 2. Adoption of agenda

The agenda was adopted as agreed.

### 3. Declarations of Interest of Working Groups members

In accordance with EFSA's Policy on Independence and Scientific Decision-Making Processes and the Decision of the Executive Director on Declarations of Interest<sup>1</sup>, EFSA screened the Annual Declaration of Interest and the Specific Declaration of Interest filled in by the working group members invited for the present meeting. No Conflicts of Interest related to the issues discussed in this meeting have been identified during the screening process or at the Oral Declaration of Interest at the beginning of this meeting.

### 4. Discussion points

The analysis done by modelling was discussed and revised. Following action points were agreed :

- Section on host demography and vaccination to be moved at the beginning
- to explain effect of herd size on the force of infection
- To indicate how vaccine effectiveness is calculated and refer to glossary
- To check text about time to detection, example about Serbia, and amend Figure 1, and add explanation about  $t_{det}$

---

<sup>1</sup> <http://www.efsa.europa.eu/en/keydocs/docs/independencerules2014.pdf>

- To add conclusions points for each sections 3.1.1 and 3.1.2 on the results of modelling duration of vaccination in Albania or in Bulgaria and Greece, and check text

The draft report was revised and following points discussed and agreed:

- To add key conclusions about chapter 3.2 (Ale)
- To revise text about diagnostic test in section 3.3.1 , to add explanatory text to the graph on diagnostic window
- To amend the title of Table 3 about time to detection, so to better explain the 3 time windows
- To add discussion and conclusion points for Table 4 about Size of surveillance zone (km), considering different kernel and Rh values
  - Number of farms inside different size surveillance zones can be estimated for Greece and Bulgaria
- Section 3.3.2 about the surveillance scenario: to add info from Paolo 's table to the 4 scenarios
  - Design prevalence: to calculate prevalence at different time to detection (2, 3, 4, weeks)
  - Calculate sample size inside a certain belt areas according to estimated design prevalence

Contributions to be circulate by 26 August.

Next WG meeting is planned on 29<sup>th</sup> August.

---

ALPHA UNIT

## Minutes of the 4th meeting of the Standing EFSA Working Group on lumpy skin disease

[EFSA-Q-2018-00289](#)

29<sup>th</sup> August 2018, Parma

(adopted on 29<sup>th</sup> August)

### Invited participants:

WG experts: Arjan STEGEMAN, Simon GUBBINS, Paolo Calistri, Annebel DEVLEESCHAUWER, Eyal KLEMENT

EFSA: Alessandro BROGLIA, Sotiria ANTONIOU, Jose CORTINHAS

### 1. Welcome and apologies for absence

The participants were welcome. Apologies from Eyal Klement.

### 2. Adoption of agenda

The agenda was adopted as agreed.

### 3. Declarations of Interest of Working Groups members

In accordance with EFSA's Policy on Independence and Scientific Decision-Making Processes and the Decision of the Executive Director on Declarations of Interest<sup>1</sup>, EFSA screened the Annual Declaration of Interest filled in by the working group members invited for the present meeting. No Conflicts of Interest related to the issues discussed in this meeting have been identified during the screening process or at the Oral Declaration of Interest at the beginning of this meeting.

### 4. Discussion points

- The draft report was revised and comments previously collected were discussed and addressed.
- The conclusion and recommendations were drafted.
- The draft is to be circulated by 31<sup>st</sup> August among the WG and comments to be sent by 3<sup>rd</sup> September.

---

<sup>1</sup> <http://www.efsa.europa.eu/en/keydocs/docs/independencerules2014.pdf>



---

ALPHA UNIT

## Minutes of the 5th meeting of the Standing EFSA Working Group on lumpy skin disease

[EFSA-Q-2018-00290](#)

(adopted on 9 October)

Teleconference, 9 Oct 2018

**Time:** 9 Oct 2018; 13.30-16.30 (Italy time)

**Participants:**

WG experts: Simon GUBBINS, Kris DeClercq, Annebel DEVLEESCHAUWER, Paolo CALISTRI, Arjan STEGEMAN, Eyal Klement

EFSA: Alessandro BROGLIA, Sotiria ANTONIOU

### 1. Welcome and apologies for absence

The participants were welcome.

### 2. Adoption of agenda

The agenda was adopted as agreed.

### 3. Declarations of Interest of Working Groups members

In accordance with EFSA's Policy on Independence and Scientific Decision-Making Processes and the Decision of the Executive Director on Declarations of Interest<sup>1</sup>, EFSA screened the Annual Declaration of Interest filled in by the working group members invited for the present meeting. No Conflicts of Interest related to the issues discussed in this meeting have been identified during the screening process or at the Oral Declaration of Interest at the beginning of this meeting.

### 4. Discussion points

- The draft presentation for GF TADs group on LSD was discussed and amended
- The summary table about the surveillance scenarios as external file to the report: was discussed and finalised.
- The agenda of the workshop on 6-7 November was discussed. Additional points proposed were discussed.

---

<sup>1</sup> <http://www.efsa.europa.eu/en/keydocs/docs/independencerules2014.pdf>

---

ALPHA UNIT

## Minutes of the 6th meeting of the Standing EFSA Working Group on lumpy skin disease

[EFSA-Q-2018-00290](#)

(adopted on 7 November)

6-7 November 2018

**Time:** 6-7 November 2018

**Participants:**

WG experts: Simon GUBBINS, Paolo CALISTRI, Arjan STEGEMAN, Eyal Klement, Andy HAEGEMAN

Hearing experts: Bafti MURATI, Tatjana LABUS, Vanja KONDRATENKO, Žaklin ACINGER-ROGIĆ, Chrysoula DILE, Aleksandar NEMET

EFSA: Alessandro BROGLIA, Sotiria ANTONIOU, Josè CORTINHAS, Drago MAROJEVIC, Nikolaus Kriz

### 1. Welcome and apologies for absence

The participants were welcome.

### 2. Adoption of agenda

The agenda was adopted as agreed.

### 3. Declarations of Interest of Working Groups members

In accordance with EFSA's Policy on Independence and Scientific Decision-Making Processes and the Decision of the Executive Director on Declarations of Interest<sup>1</sup>, EFSA screened the Annual Declaration of Interest filled in by the working group members invited for the present meeting. No Conflicts of Interest related to the issues discussed in this meeting have been identified during the screening process or at the Oral Declaration of Interest at the beginning of this meeting.

### 4. Discussion points

- The discussion points of the meeting are reported in the event report published at <https://www.efsa.europa.eu/en/topics/topic/lumpy-skin-disease>.

---

<sup>1</sup> <http://www.efsa.europa.eu/en/keydocs/docs/independencerules2014.pdf>

---

ALPHA UNIT

## Minutes of the 7th meeting of the Standing EFSA Working Group on lumpy skin disease

[EFSA-Q-2018-00290](#)

(adopted on 21 November)

Teleconference, 21 November 2018

**Time:** 21 November 2018; 14.00-17.00 (Italy time)

**Participants:**

Hearing experts: Aleksandar NEMET

EFSA: Alessandro BROGLIA, Jose CORTINHAS

### 1. Welcome and apologies for absence

The participants were welcome.

### 2. Adoption of agenda

The agenda was adopted as agreed.

### 3. Declarations of Interest of Working Groups members

In accordance with EFSA's Policy on Independence and Scientific Decision-Making Processes and the Decision of the Executive Director on Declarations of Interest<sup>1</sup>, EFSA screened the Annual Declaration of Interest filled in by the working group members invited for the present meeting. No Conflicts of Interest related to the issues discussed in this meeting have been identified during the screening process or at the Oral Declaration of Interest at the beginning of this meeting.

### 4. Discussion points

- The data from Bosnia and the possible analysis to do with those were discussed.

---

<sup>1</sup> <http://www.efsa.europa.eu/en/keydocs/docs/independencerules2014.pdf>

---

ALPHA UNIT

## Minutes of the 8th meeting of the Standing EFSA Working Group on lumpy skin disease

[EFSA-Q-2018-00290](#)

(adopted on 22 November)

Teleconference, 22 November 2018

**Time:** 22 November 2018; 14.00-17.00 (Italy time)

**Participants:**

WG experts: Paolo Calistri, Eyal Klement

Hearing experts: Zaklin Acinger Rogic

EFSA: Alessandro BROGLIA, Jose CORTINHAS

### 1. Welcome and apologies for absence

The participants were welcome.

### 2. Adoption of agenda

The agenda was adopted as agreed.

### 3. Declarations of Interest of Working Groups members

In accordance with EFSA's Policy on Independence and Scientific Decision-Making Processes and the Decision of the Executive Director on Declarations of Interest<sup>2</sup>, EFSA screened the Annual Declaration of Interest filled in by the working group members invited for the present meeting. No Conflicts of Interest related to the issues discussed in this meeting have been identified during the screening process or at the Oral Declaration of Interest at the beginning of this meeting.

### 4. Discussion points

- The data from Croatia and the possible analysis to do with those were discussed.

---

<sup>2</sup> <http://www.efsa.europa.eu/en/keydocs/docs/independencerules2014.pdf>

---

ALPHA UNIT

## Minutes of the 9th meeting of the Standing EFSA Working Group on lumpy skin disease

[EFSA-Q-2018-00290](#)

(adopted on 26<sup>th</sup> November)

Teleconference, 26 November 2018

**Time:** 26th November 2018; 14.00-17.00 (Italy time)

**Participants:**

WG experts: Paolo CALISTRI, Eyal Klement

Hearing experts: Bafti Murati

EFSA: Alessandro BROGLIA

### 1. Welcome and apologies for absence

The participants were welcome.

### 2. Adoption of agenda

The agenda was adopted as agreed.

### 3. Declarations of Interest of Working Groups members

In accordance with EFSA's Policy on Independence and Scientific Decision-Making Processes and the Decision of the Executive Director on Declarations of Interest<sup>3</sup>, EFSA screened the Annual Declaration of Interest filled in by the working group members invited for the present meeting. No Conflicts of Interest related to the issues discussed in this meeting have been identified during the screening process or at the Oral Declaration of Interest at the beginning of this meeting.

### 4. Discussion points

- The data from Kosovo and the possible analysis to do with those were discussed.

---

<sup>3</sup> <http://www.efsa.europa.eu/en/keydocs/docs/independencerules2014.pdf>

---

ALPHA UNIT

## Minutes of the 10th meeting of the Standing EFSA Working Group on lumpy skin disease

[EFSA-Q-2018-00290](#)

(adopted on 28 November)

28<sup>th</sup> November 2018

**Time:** 28 November 2018; 09.30-17.30

**Participants:**

Hearing experts: Vanja Kondratenko

EFSA: Alessandro BROGLIA, José Cortinhas

### 1. Welcome and apologies for absence

The participants were welcome.

### 2. Adoption of agenda

The agenda was adopted as agreed.

### 3. Declarations of Interest of Working Groups members

In accordance with EFSA's Policy on Independence and Scientific Decision-Making Processes and the Decision of the Executive Director on Declarations of Interest<sup>4</sup>, EFSA screened the Annual Declaration of Interest filled in by the working group members invited for the present meeting. No Conflicts of Interest related to the issues discussed in this meeting have been identified during the screening process or at the Oral Declaration of Interest at the beginning of this meeting.

### 4. Discussion points

- The data from FYROM and the possible analysis to do with those were discussed.

---

<sup>4</sup> <http://www.efsa.europa.eu/en/keydocs/docs/independencerules2014.pdf>

---

ALPHA UNIT

## Minutes of the 11th meeting of the Standing EFSA Working Group on lumpy skin disease

[EFSA-Q-2018-00290](#)

(adopted on 30 November )

Teleconference, 30 November 2018

**Time:** 30 November 2018; 14.00-17.00 (Italy time)

**Participants:**

WG experts: Paolo CALISTRI, Eyal Klement

Hearing experts: Aleksandra Miteva

EFSA: Alessandro BROGLIA

### 1. Welcome and apologies for absence

The participants were welcome. Klement sent apologies.

### 2. Adoption of agenda

The agenda was adopted as agreed.

### 3. Declarations of Interest of Working Groups members

In accordance with EFSA's Policy on Independence and Scientific Decision-Making Processes and the Decision of the Executive Director on Declarations of Interest<sup>5</sup>, EFSA screened the Annual Declaration of Interest filled in by the working group members invited for the present meeting. No Conflicts of Interest related to the issues discussed in this meeting have been identified during the screening process or at the Oral Declaration of Interest at the beginning of this meeting.

### 4. Discussion points

- The data from Bulgaria and the possible analysis to do with those were discussed.

---

<sup>5</sup> <http://www.efsa.europa.eu/en/keydocs/docs/independencerules2014.pdf>

---

ALPHA UNIT

## Minutes of the 12th meeting of the Standing EFSA Working Group on lumpy skin disease

[EFSA-Q-2018-00290](#)

(adopted on 5 December.)

Teleconference, 5<sup>th</sup> December 2018

**Time:** 5 December 2018; 09.30-17.30

**Participants:**

Hearing experts: Chrysoula DILE

EFSA: Alessandro BROGLIA, José Cortinhas, Sotiria Antoniou

### 1. Welcome and apologies for absence

The participants were welcome.

### 2. Adoption of agenda

The agenda was adopted as agreed.

### 3. Declarations of Interest of Working Groups members

In accordance with EFSA's Policy on Independence and Scientific Decision-Making Processes and the Decision of the Executive Director on Declarations of Interest<sup>6</sup>, EFSA screened the Annual Declaration of Interest filled in by the working group members invited for the present meeting. No Conflicts of Interest related to the issues discussed in this meeting have been identified during the screening process or at the Oral Declaration of Interest at the beginning of this meeting.

### 4. Discussion points

- The data from Greece and the possible analysis to do with those were discussed.

---

<sup>6</sup> <http://www.efsa.europa.eu/en/keydocs/docs/independencerules2014.pdf>



---

ALPHA UNIT

## Minutes of the 13th meeting of the Standing EFSA Working Group on lumpy skin disease

[EFSA-Q-2018-00290](#)

(adopted on 13 December)

13<sup>th</sup> December 2018

**Time:** 13 December 2018; 14.00-17.00

**Participants:**

WG experts: Simon GUBBINS, Kris DeClercq, Annebel DEVLEESCHAUWER, Paolo CALISTRI, Arjan STEGEMAN, Eyal Klement

EFSA: Alessandro BROGLIA, José Cortinhas

### 1. Welcome and apologies for absence

The participants were welcome.

### 2. Adoption of agenda

The agenda was adopted as agreed.

### 3. Declarations of Interest of Working Groups members

In accordance with EFSA's Policy on Independence and Scientific Decision-Making Processes and the Decision of the Executive Director on Declarations of Interest<sup>7</sup>, EFSA screened the Annual Declaration of Interest filled in by the working group members invited for the present meeting. No Conflicts of Interest related to the issues discussed in this meeting have been identified during the screening process or at the Oral Declaration of Interest at the beginning of this meeting.

### 4. Discussion points

- The data analysis to be included in the LSD report was discussed.

---

<sup>7</sup> <http://www.efsa.europa.eu/en/keydocs/docs/independencerules2014.pdf>

---

ALPHA UNIT

## Minutes of the 14th meeting of the Standing EFSA Working Group on lumpy skin disease

[EFSA-Q-2018-00290](#)

(adopted on 13 December)

13<sup>th</sup> December 2018

**Time:** 13 December 2018; 10.30-18.30

**Participants:**

Hearing experts: Tatjana Labus

EFSA: Alessandro BROGLIA, José Cortinhas

**1. Welcome and apologies for absence**

The participants were welcome.

**2. Adoption of agenda**

The agenda was adopted as agreed.

**3. Declarations of Interest of Working Groups members**

In accordance with EFSA's Policy on Independence and Scientific Decision-Making Processes and the Decision of the Executive Director on Declarations of Interest<sup>8</sup>, EFSA screened the Annual Declaration of Interest filled in by the working group members invited for the present meeting. No Conflicts of Interest related to the issues discussed in this meeting have been identified during the screening process or at the Oral Declaration of Interest at the beginning of this meeting.

**4. Discussion points**

- The data from Serbia and the possible analysis to do with those were discussed.

---

<sup>8</sup> <http://www.efsa.europa.eu/en/keydocs/docs/independencerules2014.pdf>

---

ALPHA UNIT

## Minutes of the 15th meeting of the Standing EFSA Working Group on lumpy skin disease

[EFSA-Q-2018-00290](#)

(adopted on 20 December)

Teleconference, 20<sup>th</sup> December 2018

**Time:** 20 December 2018; 09.00-13.00

**Participants:**

WG experts: Simon GUBBINS, Kris DeClercq, Paolo CALISTRI, Arjan STEGEMAN, Eyal Klement

EFSA: Alessandro BROGLIA, Josè Cortinhas

### 1. Welcome and apologies for absence

The participants were welcome.

### 2. Adoption of agenda

The agenda was adopted as agreed.

### 3. Declarations of Interest of Working Groups members

In accordance with EFSA's Policy on Independence and Scientific Decision-Making Processes and the Decision of the Executive Director on Declarations of Interest<sup>9</sup>, EFSA screened the Annual Declaration of Interest filled in by the working group members invited for the present meeting. No Conflicts of Interest related to the issues discussed in this meeting have been identified during the screening process or at the Oral Declaration of Interest at the beginning of this meeting.

### 4. Discussion points

- The data analysis to be included in the LSD report was discussed.

---

<sup>9</sup> <http://www.efsa.europa.eu/en/keydocs/docs/independencerules2014.pdf>

---

**ALPHA UNIT**

## **Minutes of the 16th meeting of the Standing EFSA Working Group on lumpy skin disease**

**[EFSA-Q-2018-00290](#)**

(adopted on 9 January)

Teleconference, 9 January 2019

**Time:** 9 January 2019; 14.00-17.00 (Italy time)

**Participants:**

WG experts: Simon GUBBINS, Kris DeClercq, Paolo CALISTRI, Arjan STEGEMAN, Eyal Klement

EFSA: Alessandro BROGLIA, Jose CORTINHAS, Sotiria ANTONIOU

### **1. Welcome and apologies for absence**

The participants were welcome.

### **2. Adoption of agenda**

The agenda was adopted as agreed.

### **3. Declarations of Interest of Working Groups members**

In accordance with EFSA's Policy on Independence and Scientific Decision-Making Processes and the Decision of the Executive Director on Declarations of Interest<sup>1</sup>, EFSA screened the Annual Declaration of Interest filled in by the working group members invited for the present meeting. No Conflicts of Interest related to the issues discussed in this meeting have been identified during the screening process or at the Oral Declaration of Interest at the beginning of this meeting.

### **4. Discussion points**

The draft report was discussed

#### **Section on Epidemiological situation:**

- To describe current situation where LSD is active by adding uncertainties about Turkey and Russia
- To skip box plot for morbidity ( too many confounders)
- Graph of monthly distribution of outbreaks: to add temporal lines for past years

#### **Section on vaccination progress**

- Maps of progress of vaccination + related text to be produced

---

<sup>1</sup> <http://www.efsa.europa.eu/en/keydocs/docs/independencerules2014.pdf>

## ALPHA UNIT

### Section on surveillance activities

- Data pending from FYROM and Croatia

### Section on vaccine safety

- Revision

### Section on within herd transmission (could be also moved before in the document)

- Text to be produced

Next meeting is scheduled on 30th January.

---

**ALPHA UNIT**

## **Minutes of the 17th meeting of the Standing EFSA Working Group on lumpy skin disease**

**[EFSA-Q-2018-00290](#)**

(adopted on 30 January)

Teleconference, 30 January 2019

**Time:** 30 January 2019; 14.00-17.00 (Italy time)

**Participants:**

WG experts: Simon GUBBINS, Kris DeClercq, Paolo CALISTRI, Arjan STEGEMAN,  
Eyal Klement  
EFSA: Alessandro BROGLIA, Jose CORTINHAS, Sotiria ANTONIOU

### **1. Welcome and apologies for absence**

The participants were welcome. Stegeman sent apologies

### **2. Adoption of agenda**

The agenda was adopted as agreed.

### **3. Declarations of Interest of Working Groups members**

In accordance with EFSA's Policy on Independence and Scientific Decision-Making Processes and the Decision of the Executive Director on Declarations of Interest<sup>1</sup>, EFSA screened the Annual Declaration of Interest filled in by the working group members invited for the present meeting. No Conflicts of Interest related to the issues discussed in this meeting have been identified during the screening process or at the Oral Declaration of Interest at the beginning of this meeting.

### **4. Discussion points**

The draft report was discussed and the following agreed:

- Graphs about temporal distribution to be fixed by adding a gap in the y axis
- Section on vaccination to be completed with description on surveillance as done in Croatia. Serological data from FYROM to be confirmed
- Section on within village spread to be completed with discussion points and circulated to the AHAW panel for feedback

Next meeting scheduled on 19<sup>th</sup> February.

---

<sup>1</sup> <http://www.efsa.europa.eu/en/keydocs/docs/independencerules2014.pdf>

---

ALPHA UNIT

## Minutes of the 18th meeting of the Standing EFSA Working Group on lumpy skin disease

[EFSA-Q-2018-00290](#)

(adopted on 19 February)

Teleconference, 19 February 2019

**Time:** 19 February 2019; 14.00-17.00 (Italy time)

**Participants:**

WG experts: Simon GUBBINS, Kris DeClercq, Paolo CALISTRI, Arjan STEGEMAN,  
Eyal Klement  
EFSA: Alessandro BROGLIA, Sotiria ANTONIOU

### 1. Welcome and apologies for absence

The participants were welcome. Kris DeClercq sent apologies.

### 2. Adoption of agenda

The agenda was adopted as agreed.

### 3. Declarations of Interest of Working Groups members

In accordance with EFSA's Policy on Independence and Scientific Decision-Making Processes and the Decision of the Executive Director on Declarations of Interest<sup>1</sup>, EFSA screened the Annual Declaration of Interest filled in by the working group members invited for the present meeting. No Conflicts of Interest related to the issues discussed in this meeting have been identified during the screening process or at the Oral Declaration of Interest at the beginning of this meeting.

### 4. Discussion points

The comments provided by the AHAW Panel and EC were discussed and addressed in the draft report.

---

<sup>1</sup> <http://www.efsa.europa.eu/en/keydocs/docs/independencerules2014.pdf>



UNIT Animal Health and Plant Health

# SCIENTIFIC PANEL ON ANIMAL HEALTH AND ANIMAL WELFARE

## MINUTES OF THE<sup>19</sup> MEETING OF THE WORKING GROUP ON LSD

**Held on 18 Sept 2019, web**

**(Agreed on 23 September 2019)<sup>1</sup>**

### Participants

- Working Group Members:<sup>2</sup>  
Arjan STEGEMAN, Simon GUBBINS, Paolo Calistri, Kris DECLERCQ, Eyal KLEMENT
- EFSA:  
ALPHA: Alessandro BROGLIA  
AMU: Josè CORTIÑAS

### 1. Welcome and apologies for absence

The Chair welcomed the participants.

### 2. Adoption of agenda

The agenda was adopted without changes.

### 3. Declarations of Interest of Working Groups members

In accordance with EFSA's Policy on Independence<sup>3</sup> and the Decision of the Executive Director on Competing Interest Management<sup>4</sup>, EFSA screened the Annual Declarations of Interest filled out by the Working Group members invited to the present meeting. No Conflicts of Interest related to the issues discussed in this meeting have been identified during the screening process, and no interests were declared orally by the members at the beginning of this meeting.

<sup>1</sup> Minutes should be published within 15 working days of the final day of the relevant meeting.

<sup>2</sup> Indicate first full name and then surname (John Smith) all throughout the document.

<sup>3</sup> [http://www.efsa.europa.eu/sites/default/files/corporate\\_publications/files/policy\\_independence.pdf](http://www.efsa.europa.eu/sites/default/files/corporate_publications/files/policy_independence.pdf)

<sup>4</sup> [http://www.efsa.europa.eu/sites/default/files/corporate\\_publications/files/competing\\_interest\\_management\\_17.pdf](http://www.efsa.europa.eu/sites/default/files/corporate_publications/files/competing_interest_management_17.pdf)



## 4. Scientific topic(s) for discussion

### 4.1. Item<sup>5</sup>:

- Serological data from Croatia: presentation of the analysis done : OD values in relation to time from vaccination, number of vaccinations, age
- Action points (**AP** for EFSA):
  - need to organise the data set according to ID of the animals , and check how many times the same animals were tested with results and OD and vaccination
  - to check if we can get the OD values also for negative animals
- presentation by Eyal about the recrudescence of lumpy skin disease in Israel in 2019 , Eyal (**AP**) to draft in summarised the situation in Israel and to indicate some lessons learned for the European countries
- to update the epidemiological situation with outbreaks in Bangladesh and in Palestine , and mention the suspected outbreak in India (**AP**, EFSA)
- to update information regarding outbreaks in Russia (**AP**, EFSA)
- Kris (**AP**): to check vaccination status in Kazakhstan

## 5. Next WG meetings and timeline:

23 October	Web conference on LSD
6-7 November	LSD workshop in Parma
10-11 December	Physical meeting in Parma

---

<sup>5</sup> Please add the following link to the EFSA's register of questions and substitute YYYY and NNNNN accordingly  
<http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-YYYY-NNNNN>



UNIT Animal Health and Plant Health

# SCIENTIFIC PANEL ON ANIMAL HEALTH AND ANIMAL WELFARE

## MINUTES OF THE 20<sup>th</sup> MEETING OF THE STANDING WORKING GROUP ON LSD

**Held on 23 October 2019, web**

**(Agreed on 28 October 2019)<sup>1</sup>**

### Participants

■ Working Group Members:<sup>2</sup>

Arjan STEGEMAN, Simon GUBBINS, Paolo Calistri, Kris DECLERCQ, Eyal KLEMENT

■ EFSA:

ALPHA: Alessandro BROGLIA , Sotiria Eleni ANTONIOU

### 1. Welcome and apologies for absence

The Chair welcomed the participants. Eyal Klement sent apologies

### 2. Adoption of agenda

The agenda was adopted without changes.

### 3. Declarations of Interest of Working Groups members

In accordance with EFSA's Policy on Independence<sup>3</sup> and the Decision of the Executive Director on Competing Interest Management<sup>4</sup>, EFSA screened the Annual Declarations of Interest filled out by the Working Group members invited to the present meeting. No Conflicts of Interest related to the issues discussed in this meeting have been identified during the screening process, and no interests were declared orally by the members at the beginning of this meeting.

<sup>1</sup> Minutes should be published within 15 working days of the final day of the relevant meeting.

<sup>2</sup> Indicate first full name and then surname (John Smith) all throughout the document.

<sup>3</sup> [http://www.efsa.europa.eu/sites/default/files/corporate\\_publications/files/policy\\_independence.pdf](http://www.efsa.europa.eu/sites/default/files/corporate_publications/files/policy_independence.pdf)

<sup>4</sup> [http://www.efsa.europa.eu/sites/default/files/corporate\\_publications/files/competing\\_interest\\_management\\_17.pdf](http://www.efsa.europa.eu/sites/default/files/corporate_publications/files/competing_interest_management_17.pdf)

## 4. Scientific topic(s) for discussion

### 4.1. Item discussed<sup>5</sup>:

- Feedback from GF TADs on LSD held in Athens on 16-17 October was given to the WG, especially the fact that in 2020 the cessation of LSD vaccination will be proposed.
- Vaccination data from Turkey related to the province of Aydin were discussed: anyway there is the need to have the full dataset for all villages in the province, or at least trying to match vaccination data with ADNS data (Ale, Simon).
- Surveillance data from Croatia: difficulties to get OD values were communicated. Instead a possibility is to work with binary outcome of ELISA (pos/neg) and test towards number of vaccination and time lag from vaccination. Some animals have also multiple tests at different dates, the negativisation over time can be checked (Ale, Josè, Sotiria).
- The agenda for workshop 6-7 November was discussed and agreed. Focus will be on surveillance design. Work is distributed about the preparation of the presentations. A template will be distributed to the country representatives to bring information about the surveillance they have in place.
- Review of next report: a section about the survey on side effects of LSD vaccine on milk loss can be included (Eyal), as well as a section recalling how to design a surveillance after stop of vaccination.

## 5. Next WG meetings and timeline:

6-7 November	LSD workshop in Parma
10-11 December (from lunch to lunch)	Physical meeting in Parma

---

<sup>5</sup> Please add the following link to the EFSA's register of questions and substitute YYYY and NNNNN accordingly <http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-YYYY-NNNNN>



UNIT Animal Health and Plant Health

# SCIENTIFIC PANEL ON ANIMAL HEALTH AND ANIMAL WELFARE

## MINUTES OF THE 21<sup>th</sup> MEETING OF THE STANDING WORKING GROUP ON LSD

**Held on 6-7 November, Parma**

**(Agreed on 14/11/2019 2019)<sup>1</sup>**

### Participants

- Working Group Members:<sup>2</sup> Arjan STEGEMAN, Simon GUBBINS, Paolo Calistri, Andy HAEGEMAN, Eyal KLEMENT, Miguel MIRANDA
- Hearing experts: Aleksandra MITEVA , Anil DEMELI, Bafti MURATI, Chrysoula DILE, Tatjana LABUS, Vanja KONDRATENKO, Aleksandar NEMET, Žaklin ACINGER-ROGIĆ, Blerina LUKE, Ali LILO
- EFSA: Alessandro BROGLIA , Sotiria Eleni ANTONIOU, Jose Cortinhas, Yves VAN DER STEDE, Drago MAROJEVIC

### 1. Welcome and apologies for absence

The participants were welcomed. Aleksandar NEMET sent apologies.

### 2. Adoption of agenda

The agenda was adopted without changes.

### 3. Declarations of Interest of Working Groups members

In accordance with EFSA's Policy on Independence<sup>3</sup> and the Decision of the Executive Director on Competing Interest Management<sup>4</sup>, EFSA screened the Annual Declarations of Interest filled out by the Working Group members invited to the present meeting. No Conflicts of Interest related to the

<sup>1</sup> Minutes should be published within 15 working days of the final day of the relevant meeting.

<sup>2</sup> Indicate first full name and then surname (John Smith) all throughout the document.

<sup>3</sup> [http://www.efsa.europa.eu/sites/default/files/corporate\\_publications/files/policy\\_independence.pdf](http://www.efsa.europa.eu/sites/default/files/corporate_publications/files/policy_independence.pdf)

<sup>4</sup> [http://www.efsa.europa.eu/sites/default/files/corporate\\_publications/files/competing\\_interest\\_management\\_17.pdf](http://www.efsa.europa.eu/sites/default/files/corporate_publications/files/competing_interest_management_17.pdf)

issues discussed in this meeting have been identified during the screening process, and no interests were declared orally by the members at the beginning of this meeting.

## 4. Scientific topic(s) for discussion

### 4.1. Item discussed<sup>5</sup>:

- The country representatives presented the current situation on LSD outbreaks, vaccination and surveillance so far and planned for 2020
- Eyal Klement presented the LSD epidemics in 2019 in Israel and some lesson learnt especially about stockpiling vaccines and continue vaccination on the borders.
- Andy Haegeman from Sciensano presented some results from experiment on LSD transmission with different type of vectors, stable fly, horse fly and ticks, and the time lag for flies being infected
- Some preliminary results of vector trapping from North Macedonia were shown
- About how to monitor side effects of LSD vaccination, Eyal Klement presented some preliminary results and survey setting for estimating the milk loss after LSD vaccination.
- A discussion about how to monitor LSD vectors in the field was held; preliminary results from North Macedonia were shown about trapping by UV light trap. Vector competence and vector capacity are both important aspects for clarifying the vector species implied in the LSD transmission.
- The outline of next LSD report, including the update on epidemiological situation in Europe and Asia, the vaccine and immunisation coverage, and possible analysis of surveillance results from Croatia.
- It was reminded about SIGMA project, the reason behind and opportunities for MSs and IPA countries
- The different surveillance options for LSD in different scenarios, as referred in the report on exit strategy was presented.
- As practical exercise, the calculation of the sample size under different surveillance objectives and risk based approach was conducted, by using the RIBESS tool. Further information and support can be provided by EFSA.
- A discussion was held on possible surveillance for LSD, considering EFSA recommendations, how to design and adapt LSD surveillance in different countries and context, how could EFSA technically support the affected countries in surveillance designing.

## 5. Next WG meetings and timeline:

The next meeting for the WG members will be held on 10-11<sup>th</sup> December.

---

<sup>5</sup> Please add the following link to the EFSA's register of questions and substitute YYYY and NNNNN accordingly <http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-YYYY-NNNNN>



UNIT Animal Health and Plant Health

# SCIENTIFIC PANEL ON ANIMAL HEALTH AND ANIMAL WELFARE

## MINUTES OF THE 22<sup>nd</sup> MEETING OF THE WORKING GROUP ON LSD

**Held on 10-11 Dec 2019, Parma**

**(Agreed on 16th December 2019)<sup>1</sup>**

### Participants

- Working Group Members:<sup>2</sup>  
Arjan STEGEMAN, Simon GUBBINS, Paolo Calistri, Kris DECLERCQ, Eyal KLEMENT
- EFSA:  
ALPHA: Alessandro BROGLIA , Sotiria Eleni ANTONIOU

### 1. Welcome and apologies for absence

The Chair welcomed the participants. Apologies by Paolo Calistri.

### 2. Adoption of agenda

The agenda was adopted without changes.

### 3. Declarations of Interest of Working Groups members

In accordance with EFSA's Policy on Independence<sup>3</sup> and the Decision of the Executive Director on Competing Interest Management<sup>4</sup>, EFSA screened the Annual Declarations of Interest filled out by the Working Group members invited to the present meeting. No Conflicts of Interest related to the issues discussed in this meeting have been identified during the screening process, and no interests were declared orally by the members at the beginning of this meeting.

<sup>1</sup> Minutes should be published within 15 working days of the final day of the relevant meeting.

<sup>2</sup> Indicate first full name and then surname (John Smith) all throughout the document.

<sup>3</sup> [http://www.efsa.europa.eu/sites/default/files/corporate\\_publications/files/policy\\_independence.pdf](http://www.efsa.europa.eu/sites/default/files/corporate_publications/files/policy_independence.pdf)

<sup>4</sup> [http://www.efsa.europa.eu/sites/default/files/corporate\\_publications/files/competing\\_interest\\_management\\_17.pdf](http://www.efsa.europa.eu/sites/default/files/corporate_publications/files/competing_interest_management_17.pdf)

## 4. Scientific topic(s) for discussion

### 4.1. Item<sup>5</sup>:

- The draft report has been revised, key messages drafted
- Section on serological survey in Croatia has been reshuffled.
- Section on surveillance discussed, decided to calculate sample size based on herds.

To be done:

- Amend vaccination map according to data received by countries
- Recalculate the sample size for surveillance based on herds
- Cross check section about Turkey and Russia with colleagues
- Draft section on papers published in 2019 on diagnostics
- Check section on side effects in Israel
- Draft section on conclusion and recommendations

## 5. Next WG meetings and timeline:

15 Jan 2020	Web conference on LSD (9.30-12.30)
31 Jan 2020	Deadline for approval by RASA Department of EFSA

---

<sup>5</sup> Please add the following link to the EFSA's register of questions and substitute YYYY and NNNNN accordingly  
<http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-YYYY-NNNNN>



UNIT Animal Health and Plant Health

# SCIENTIFIC PANEL ON ANIMAL HEALTH AND ANIMAL WELFARE

## MINUTES OF THE 23<sup>rd</sup> MEETING OF THE WORKING GROUP ON LSD

**Held on 15<sup>th</sup> Jan 2020**

**(Agreed on 15<sup>th</sup> Jan 2020)<sup>1</sup>**

### Participants

■ Working Group Members:<sup>2</sup>

Arjan STEGEMAN, Simon GUBBINS, Paolo Calistri, Kris DECLERCQ, Eyal KLEMENT

■ EFSA:

ALPHA: Alessandro BROGLIA , Sotiria Eleni ANTONIOU

### 1. Welcome and apologies for absence

The Chair welcomed the participants. Apologies by Paolo Calistri.

### 2. Adoption of agenda

The agenda was adopted without changes.

### 3. Declarations of Interest of Working Groups members

In accordance with EFSA's Policy on Independence<sup>3</sup> and the Decision of the Executive Director on Competing Interest Management<sup>4</sup>, EFSA screened the Annual Declarations of Interest filled out by the Working Group members invited to the present meeting. No Conflicts of Interest related to the issues discussed in this meeting have been identified during the screening process, and no interests were declared orally by the members at the beginning of this meeting.

<sup>1</sup> Minutes should be published within 15 working days of the final day of the relevant meeting.

<sup>2</sup> Indicate first full name and then surname (John Smith) all throughout the document.

<sup>3</sup> [http://www.efsa.europa.eu/sites/default/files/corporate\\_publications/files/policy\\_independence.pdf](http://www.efsa.europa.eu/sites/default/files/corporate_publications/files/policy_independence.pdf)

<sup>4</sup> [http://www.efsa.europa.eu/sites/default/files/corporate\\_publications/files/competing\\_interest\\_management\\_17.pdf](http://www.efsa.europa.eu/sites/default/files/corporate_publications/files/competing_interest_management_17.pdf)



## 4. Scientific topic(s) for discussion

### 4.1. Item<sup>5</sup>:

- The draft report has been revised, conclusions and recommendations checked

## 5. Next WG meetings and timeline:

15 Jan 2020	This was the last meeting foreseen by this mandate
31 Jan 2020	Deadline for approval by RASA Department of EFSA

---

<sup>5</sup> Please add the following link to the EFSA's register of questions and substitute YYYY and NNNNN accordingly  
<http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-YYYY-NNNNN>